199658-92-9

Usage

Type of Compound

Synthetic small molecule

Target

Vascular endothelial growth factor receptor (VEGFR)

Mechanism of Action

Inhibition of VEGFR activity

Potential Therapeutic Applications

Treatment of angiogenesis-dependent diseases

Angiogenesis-Dependent Diseases

Cancer, certain eye disorders

Additional Effects

Inhibition of cancer cell growth and proliferation

Current Status

Research on pharmacological properties and clinical applications is ongoing

InChI:InChI=1/C14H13BrN2O2/c15-9-3-4-12-10(7-9)11(8-16-12)13(18)14(19)17-5-1-2-6-17/h3-4,7-8,16H,1-2,5-6H2

Upstream product

• 123-75-1 pyrrolidine 
• 63843-81-2 2-(5-bromo-1H-indol-3-yl)-2-oxoacetyl chloride 
• 10075-50-0 5-bromo-1H-indole 

Downstream Products

• 17274-68-9 5-bromo-3-(2-(pyrrolidin-1-yl)ethyl)-1H-indole 
• 208464-62-4 5-(1-aza-1-benzylcyclohex-3-en-4-yl)-3-(2-pyrrolidinylethyl)-1H-indole 
• 208464-44-2 5-bromo-3-(2-pyrrolidinylethyl)-1-benzoylindole 
• 208464-69-1 5-Cyclohexyl-3-(2-pyrrolidinylethyl)-1H-indole 
• 208464-61-3 5-(cyclohex-1-en-1-yl)-3-(2-pyrrolidinylethyl)-1H-indole 
• 208464-52-2 5-(1-hydroxycyclohex-1-yl)-3-(2-pyrrolidinylethyl)-1H-indole 
• 208464-79-3 C₂₆H₂₈N₂O₂ 

Relevant academic research and scientific papers

5-Thienyltryptamine derivatives as serotonin 5-HT(1B/1D) receptor agonists: Potential treatments for migraine

A series of 5-(2- or 3-thienyl)tryptamine derivatives (9) has been synthesized and shown to be potent and selective 5-HT(1D) versus 5-HT(1B) receptor agonists and, therefore, potential treatments for migraine. (C) 2000 Elsevier Science Ltd. All rights reserved.

Synthesis and evaluation of indole-based new scaffolds for antimicrobial activities - Identification of promising candidates

Search for new antimicrobial agents led to the synthesis of series of N-1, C-3 and C-5 substituted bis-indoles. Their evaluation for antifungal and antibacterial activities resulted in the optimization of pyrrolidine/morpholine/ N-benzyl moiety at the C-3 end and propane/butane/xylidine groups as linkers between two indoles for significant inhibition of microbial growth. Preliminary investigations have identified three highly potent antimicrobial agents. Dockings of these molecules in the active sites of lanosterol demethylase, dihydrofolate reductase and topoisomerase II indicate their strong interactions with these enzymes.

3-(2-Pyrrolidin-1-ylethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives as high affinity human 5-HT1B/1D ligands

A series of 3-(2-pyrrolidin-1-ylethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)- 1H-indole derivatives (2) has been prepared using parallel synthesis techniques, and their structure-activity relationships studied. High affinity human 5-HT1B/1D (h5-HT1B/1D) ligands have been identified.

5-CYCLO INDOLE COMPOUNDS AS 5-HT1D RECEPTOR LIGANDS

Described herein are compounds selective for a 5-HT1D-like receptor, which have general formula (I), wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO2 and NR; R is selected from H and OH; n is 0 or 1 as permitted by chemical structure; R is selected from CRRCH2NRR or a group of formula (II), (III) or (IV); R is selected from H and benzoyl; R is selected from H, loweralkyl, benzyl, loweralkylcarbonyl, loweralkylaminocarbonyl; loweralkylaminothiocarbonyl, loweralkanoyl, loweralkylaminoimide and loweralkoxy-substituted loweralkylene; R and R are independently selected from H, loweralkoxy and hydroxy; R and R are independently selected from H and loweralkyl or R and R form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring; ----- denotes a single or double bond; and R, R and R are independently selected from H and loweralkyl. Also described is the use of these compounds as pharmaceuticals to treat indications where stimulation of a 5-HT1D-like receptor is implicated, such as migraine.